<DOC>
	<DOCNO>NCT00594256</DOCNO>
	<brief_summary>The present protocol proposes study recently approve compound sodium oxybate ( Xyrem ) , gamma-aminobutyric acid type b ( GABAB ) g-hydroxybutyric acid ( GHB ) receptor agonist , study persistent symptom schizophrenia . Sodium oxybate central nervous system depressant currently approve treatment narcolepsy associate cataplexy excessive daytime sleepiness . In addition evaluate effect sodium oxybate persistent symptom neurocognitive deficit schizophrenia , study test hypothesis medication may particularly effective combat Insomnia Related Schizophrenia , normalize symptomatic polysomnographic manifestation sleep-related brain dysfunction schizophrenia .</brief_summary>
	<brief_title>Sodium Oxybate Schizophrenia With Insomnia</brief_title>
	<detailed_description>Rationale/Study Hypothesis : Rationale study sodium oxybate twofold : first , sleep dysfunction important overlook aspect schizophrenia intrinsically link cognitive functional impairment , , second , GABAB receptor regulate dopaminergic glutamatergic system vivo , suggest GABAB agonist may therapeutically beneficial schizophrenia . We aware three previous trial GHB schizophrenia , two show overall benefit psychopathology . We note multiple limitation control trial , include : 1. requirement cumbersome dosing pattern ( six time day ) could lead incomplete compliance , 2. lack objective measure subjective sleep sleep architecture , 3. lack objective cognitive testing , 4. use GHB monotherapy conjunction low dose antipsychotic , 5. short trial duration ( le 4 week ) , 6. relatively low overall night-time dose GHB , 7. heterogeneous , small sample . We propose open label , proof concept study evaluate effect sodium oxybate insomnia schizophrenia . The primary hypothesis study patient treat sodium oxybate show improve subjective sleep measure overall Epworth Sleepiness Scale Pittsburgh Sleep Quality Index . Secondarily , expect superior reduction total psychopathology PANSS factor scale ( PANSS ) , polysomnographic measure , neurocognition ( MATRICS ) . Design dosage schedule : We plan enroll eight hospitalize patient diagnostic &amp; statistical manual text revision ( DSM-IV-TR ) schizophrenia insomnia relate schizophrenia . The study include : one-week evaluation period , include taper hypnotic , baseline diagnostic , psychopathology , neurocognitive , electrophysiological polysomnographic measurement . Patients begin four-week trial adjunctive sodium oxybate , three-week taper sodium oxybate follow . Hypnotic/sodium oxybate taper may extend abbreviate , depend clinical judgment . Patients enter study permit receive typical atypical antipsychotic . Treating psychiatrist encourage maintain fixed dos psychotropic medication throughout study . Other haloperidol benztropine prn ( 10 mg/day haloperidol ) , prescription new psychotropic permit . After second week study medication , subject require 4 dos haloperidol one week consider relapse , withdrawn study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Patients age 1845 DSMIV diagnosis schizophrenia insomnia relate schizophrenia , confirm structure interview ( SCID ) . Lack capacity give inform consent ( capacity determine licensed member treatment team ) . Unstable medical illness . Diagnosis restless leg syndrome , seizure disorder , uncontrolled hypertension , unstable cardiac illness , obstructive sleep apnea . Pregnancy lack adequate birth control . History substance dependence disorder . Current treatment valproic acid . Succinic semialdehyde dehydrogenase deficiency ( SSADH ) . Persistent need treatment benzodiazepine , barbiturate , opiate sedative hypnotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Sleep Architecture</keyword>
	<keyword>Sodium Oxybate</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Cognition</keyword>
</DOC>